#BEGIN_DRUGCARD DB08866

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Estradiol undergoes an extensive first-pass effect and a considerable part of the dose administered is already metabolized in the gastrointestinal mucosa. The CYP 3A family is known to play the most important role in human estradiol metabolism. The main metabolites are estrone and its sulfate or glucuronide conjugates.
Dienogest is extensively metabolized by the known pathways of steroid metabolism (hydroxylation, conjugation), with the formation of mostly inactive metabolites. CYP3A4 was identified as a predominant enzyme catalyzing the metabolism of dienogest.

# Brand_Mixtures:
Not Available

# Brand_Names:
Natazia
Qlaira

# CAS_Registry_Number:
65928-58-7

# ChEBI_ID:
Not Available

# Chemical_Formula:
C43H57NO5

# Chemical_IUPAC_Name:
2-[(10S,11S,14R,15S)-14-hydroxy-15-methyl-5-oxotetracyclo[8.7.0.0Â²,â?·.0Â¹Â¹,Â¹â?µ]heptadeca-1,6-dien-14-yl]acetonitrile (1S,10R,11S,14S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0Â²,â?·.0Â¹Â¹,Â¹â?µ]heptadeca-2(7),3,5-trien-14-yl pentanoate

# Chemical_Structure:
Not Available

# Creation_Date:
2013-04-26 21:49:06 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Estradiol valerate/Dienogest is a Combined oral contraceptive (COC) indicated for use by women to prevent pregnancy. It is also indicated for the treatment of heavy menstrual bleeding in women.

The efficacy of Estradiol valerate/Dienogest in women with a body mass index of 
>30 kg/m2 has not been evaluated.

# Dosage_Forms:
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral

# Drug_Category:
Contraceptive Agents, Female

# Drug_Interactions:
Bosentan	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Carbamazepine	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Dexamethasone	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Efavirenz	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Fosphenytoin	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Nafcillin	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Nevirapine	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Ospemifene	Pharmacodynamic synergist; contraindicated.
Pentobarbital	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Phenobarbital	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Phenytoin	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Primidone	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Rifabutin	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
Rifapentine	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.
St. John's Wort	Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.

# Drug_Reference:
21917554	Whalen KL, Rose R: Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother. 2011 Oct;45(10):1256-61. doi: 10.1345/aph.1Q216. Epub 2011 Sep 13.
22240178	Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M: Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012 Aug;86(2):96-101. doi: 10.1016/j.contraception.2011.11.011. Epub 2012 Jan 10.
22364708	Ruan X, Seeger H, Mueck AO: The pharmacology of dienogest. Maturitas. 2012 Apr;71(4):337-44. doi: 10.1016/j.maturitas.2012.01.018. Epub 2012 Feb 24.
23586801	Wasiak R, Filonenko A, Vanness DJ, Law A, Jeddi M, Wittrup-Jensen KU, Stull DE, Siak S, Jensen JT: Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013 Apr;22(4):378-84. doi: 10.1089/jwh.2012.3633.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
<1 mg/mL

# Food_Interactions:
Grapefruit juice may increase plasma concentrations of dienogest. (CYP3A4 inhibitor)

# GenBank_ID:
Not Available

# Generic_Name:
Estradiol valerate/Dienogest

# HET_ID:
Not Available

# Half_Life:
The terminal half-life of estradiol is approximately 14 hours.
The terminal half-life of dienogest is approximately 11 hours.

# InChI_Identifier:
InChI=1S/C23H32O3.C20H25NO2/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2;1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3;12,17-18,23H,2-10H2,1H3/t18-,19-,20+,21+,23+;17-,18+,19+,20-/m11/s1

# InChI_Key:
InChIKey=LRHSUZNWLAJWRT-GAJBHWORSA-N

# Indication:
Indicated for use by women for pregnancy prevention.
Also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of birth control.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01413

# LIMS_Drug_ID:
8876

# Mechanism_Of_Action:
Estradiol valerate/Dienogest lower the risk of becoming pregnant primarily by suppressing ovulation. Additionally, cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation are other possible mechanisms.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
667.9164

# Molecular_Weight_Mono:
667.423673939

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Estradiol valerate is a synthetic prodrug of 17ÃŸ-estradiol, while dienogest (DNG) is a progestin. DNG displays properties of 19-nortestosterone derivatives as well as properties associated with progesterone derivatives.

# Predicted_LogP_Hydrophobicity:
5.28

# Predicted_LogS:
-5.8

# Predicted_Water_Solubility:
6.17e-04 g/l

# Primary_Accession_No:
DB08866

# Protein_Binding:
~90%

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/natazia-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H].[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
17-hydroxy-3-oxo-19-nor-17Î±-pregna-4,9-diene-21-nitrile
17Î±-cyanomethyl-17Î²-hydroxy-estra-4,9(10)-dien-3-one
17Î²-Estradiol-17-valerate
Natazia
Qlaira
pentanoate d'estra-1,3,5(10)-triÃ¨ne-3-ol-17Î²-yle

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-04-28 13:44:23 -0600

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

#END_DRUGCARD DB08866
